Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan
Dato-DXd offers a promising treatment option for heavily pretreated patients with HR+/HER2- breast cancer and EGFR-mutant NSCLC, providing meaningful clinical benefit with a manageable safety profile. Optimal sequencing and positioning within the rapidly shifting ADC landscape requires further investigation.
Authors
- Zachery Halford (ORCID: https://orcid.org/0000-0002-7032-0398)
- Lauren Thornburg (ORCID: https://orcid.org/0000-0003-2710-9447)
- Rachel Lucky (ORCID: https://orcid.org/0009-0009-8419-1230)
Institutions
- Union University (US)
- Regional Medical Center (US)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/10600280251393259
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00